Sign in
4

Changes in Ownership

Seres Therapeutics, Inc. Filed Acc 0000899243-18-018520

President and CEO sold 64,967 shares at an average $9.16 ($595,045)

  • President and CEO acquired 54,503 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Pomerantz Roger · President and CEO

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2018-06-25 Exercise or conversion : show line 1 in the form +16,288 $0.71 $11,564 255,056 D
2018-06-25 Sale : show line 2 in the form −26,752 $9.21 $246,504 228,304 D
2018-06-26 Exercise or conversion : show line 3 in the form +21,224 $0.71 $15,069 249,528 D
2018-06-26 Sale : show line 4 in the form −21,224 $9.19 $195,133 228,304 D
2018-06-27 Exercise or conversion : show line 5 in the form +16,991 $0.71 $12,064 245,295 D
2018-06-27 Sale : show line 6 in the form −16,991 $9.03 $153,408 228,304 D
Open-market sales · 64,967 sh · avg $9.16 · $595,045

Table II: Derivative

3 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2018-06-25 Exercise or conversion : show line 7 in the form STOCK OPTION (RIGHT TO BUY) −16,288 $0.71 2024-08-07 16,288 895,153 D
2018-06-26 Exercise or conversion : show line 8 in the form STOCK OPTION (RIGHT TO BUY) −21,224 $0.71 2024-08-07 21,224 873,929 D
2018-06-27 Exercise or conversion : show line 9 in the form STOCK OPTION (RIGHT TO BUY) −16,991 $0.71 2024-08-07 16,991 856,938 D
Loading xslF345X03/doc4.xml…